NASDAQ:DSGN Design Therapeutics (DSGN) Stock Price, News & Analysis → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free DSGN Stock Alerts $4.61 +0.04 (+0.88%) (As of 10:03 AM ET) Add Compare Share Share Today's Range$4.53▼$4.7250-Day Range$2.48▼$4.7752-Week Range$1.94▼$8.31Volume20,326 shsAverage Volume280,496 shsMarket Capitalization$260.42 millionP/E RatioN/ADividend YieldN/APrice Target$6.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Design Therapeutics alerts: Email Address Design Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside41.6% Upside$6.60 Price TargetShort InterestBearish9.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 16 Articles This WeekInsider TradingAcquiring Shares$99,750 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.02) to ($1.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.17 out of 5 starsMedical Sector571st out of 925 stocksPharmaceutical Preparations Industry269th out of 430 stocks 3.1 Analyst's Opinion Consensus RatingDesign Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageDesign Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Design Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.06% of the float of Design Therapeutics has been sold short.Short Interest Ratio / Days to CoverDesign Therapeutics has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Design Therapeutics has recently increased by 25.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDesign Therapeutics does not currently pay a dividend.Dividend GrowthDesign Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DSGN. Previous Next 2.6 News and Social Media Coverage News SentimentDesign Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Design Therapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for DSGN on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Design Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Design Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,750.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders25.70% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.64% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Design Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Design Therapeutics are expected to decrease in the coming year, from ($1.02) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Design Therapeutics is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Design Therapeutics is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDesign Therapeutics has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Design Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Design Therapeutics Stock (NASDAQ:DSGN)Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Read More DSGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DSGN Stock News HeadlinesMay 13, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Design Therapeutics, Inc. (NASDAQ:DSGN) Lifted by AnalystMay 10, 2024 | finance.yahoo.comDesign Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic ReviewMay 13, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.May 10, 2024 | markets.businessinsider.comHold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial ReviewMay 9, 2024 | americanbankingnews.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Recommendation of "Hold" from AnalystsMay 9, 2024 | msn.comDSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024May 8, 2024 | globenewswire.comDesign Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesMay 8, 2024 | americanbankingnews.comDesign Therapeutics (NASDAQ:DSGN) Upgraded to Overweight at Piper SandlerMay 13, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.May 7, 2024 | msn.comPiper Sandler Upgrades Design Therapeutics (DSGN)May 7, 2024 | msn.comDesign Therapeutics climbs as Piper Sandler upgrades on pipelineMay 7, 2024 | markets.businessinsider.comBuy Rating Justified by Design Therapeutics’ Innovative Pipeline and Solid FinancialsMay 7, 2024 | globenewswire.comDesign Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceMarch 27, 2024 | finance.yahoo.comIndependent Director of Design Therapeutics Picks Up 88% More StockMarch 26, 2024 | msn.comDesign Therapeutics And 2 Other Stocks Under $5 Insiders Are BuyingMarch 21, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)March 21, 2024 | markets.businessinsider.comHold Rating Maintained for Design Therapeutics Amid Drug Reformulation and Program UpdatesMarch 20, 2024 | stockhouse.comDesign Therapeutics Outlines Progress Across GeneTAC(TM) Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 19, 2024 | investorplace.comDSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023March 19, 2024 | finance.yahoo.comDesign Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline ProgressMarch 19, 2024 | globenewswire.comDesign Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 18, 2024 | investing.comDesign Therapeutics Inc (DSGN)March 18, 2024 | benzinga.comEarnings Preview For Design TherapeuticsMarch 15, 2024 | finance.yahoo.comDSGN Jul 2024 2.500 putMarch 15, 2024 | finance.yahoo.comDSGN Apr 2024 7.500 putMarch 12, 2024 | globenewswire.comDesign Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio UpdateFebruary 9, 2024 | benzinga.comSR ONE CAPITAL PARTNERS I, LP's Net WorthSee More Headlines Receive DSGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today5/13/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DSGN CUSIPN/A CIK1807120 Webwww.designtx.com Phone858-293-4900FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$6.60 High Stock Price Target$12.00 Low Stock Price Target$4.00 Potential Upside/Downside+44.4%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.79% Return on Assets-19.89% Debt Debt-to-Equity RatioN/A Current Ratio38.61 Quick Ratio29.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.77 per share Price / Book0.96Miscellaneous Outstanding Shares56,490,000Free Float40,789,000Market Cap$258.16 million OptionableOptionable Beta1.83 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Pratik Shah Ph.D. (Age 54)Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Comp: $638.46kDr. Sean Jeffries Ph.D. (Age 44)Chief Operating Officer Comp: $572.21kDr. Aseem Z. Ansari Ph.D.Co-Founder & Scientific AdvisorMs. Julie D. Burgess CPAChief Accounting OfficerDr. Jae B. Kim FACC (Age 54)M.D., Chief Medical Officer Ms. Dawn GiangiulioControllerMore ExecutivesKey CompetitorsContineum TherapeuticsNASDAQ:CTNMPyxis OncologyNASDAQ:PYXSImmutepNASDAQ:IMMP2seventy bioNASDAQ:TSVTNektar TherapeuticsNASDAQ:NKTRView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 288,803 shares on 5/10/2024Ownership: 2.276%Acadian Asset Management LLCBought 222,805 shares on 5/10/2024Ownership: 0.714%State Board of Administration of Florida Retirement SystemBought 12,630 shares on 5/9/2024Ownership: 0.022%Bleakley Financial Group LLCBought 11,495 shares on 5/8/2024Ownership: 0.020%SG Americas Securities LLCSold 7,541 shares on 5/7/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions DSGN Stock Analysis - Frequently Asked Questions Should I buy or sell Design Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares. View DSGN analyst ratings or view top-rated stocks. What is Design Therapeutics' stock price target for 2024? 6 analysts have issued 12-month price targets for Design Therapeutics' shares. Their DSGN share price targets range from $4.00 to $12.00. On average, they expect the company's stock price to reach $6.60 in the next twelve months. This suggests a possible upside of 41.6% from the stock's current price. View analysts price targets for DSGN or view top-rated stocks among Wall Street analysts. How have DSGN shares performed in 2024? Design Therapeutics' stock was trading at $2.65 at the beginning of the year. Since then, DSGN shares have increased by 75.8% and is now trading at $4.66. View the best growth stocks for 2024 here. When is Design Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our DSGN earnings forecast. How were Design Therapeutics' earnings last quarter? Design Therapeutics, Inc. (NASDAQ:DSGN) released its earnings results on Tuesday, March, 19th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.11. When did Design Therapeutics IPO? Design Therapeutics (DSGN) raised $228 million in an initial public offering on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are Design Therapeutics' major shareholders? Design Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.28%), BML Capital Management LLC (1.56%), Acadian Asset Management LLC (0.71%), Assenagon Asset Management S.A. (0.62%), GSA Capital Partners LLP (0.38%) and Mirae Asset Global Investments Co. Ltd. (0.03%). Insiders that own company stock include Arsani William, Deepa Prasad, Joao Md Siffert, John P Schmid, Rodney W Lappe, Simeon George, Sr One Capital Fund I Aggregat and Stella Xu. View institutional ownership trends. How do I buy shares of Design Therapeutics? Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DSGN) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThis 1 Biotech Stock has been shocking the marketsHuge AlertsNext President (Not Trump. Not Biden.)The Freeport SocietyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.